Adam is a leader in McKinsey’s Pharmaceuticals and Medical Products and Global Public Health practices and he leads our Social Sector Practice in the Americas. He has worked extensively with pharmaceutical companies, biotechnology firms, not for profits, and government agencies in many parts of the world. His particular focus is on supporting commercial and operational improvement in the vaccines, biologics, and sterile-injectables arenas.
With his private-sector clients, he has helped shape these high-growth markets, defining strategies to continue the strong growth trajectory in vaccines, shaping the development of the biosimilars space from its early days, and evolving the performance of the sterile-injectables market.
In his work with global health institutions and not for profits, Adam has helped tackle some of the world’s most difficult problems: transforming the developing-country supply ofr vaccines, helping define new strategies to combat infectious diseases, and accelerating the introduction and uptake of new vaccines.
Adam speaks frequently at industry events, including providing the keynote addresses at BIO and the World Vaccine Congress and serving on World Health Organization expert consultations on a range of infectious disease topics.
“From science to operations: Questions, choices and strategies for success in biopharma” (PDF–790 KB), McKinsey & Company, September 2014
Kellogg School of Management, Northwestern University
BA (with honors), economics and applied math